Estimating the economic burden of influenza on the older population in Malaysia.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
07
2023
accepted:
30
10
2023
medline:
20
11
2023
pubmed:
17
11
2023
entrez:
16
11
2023
Statut:
epublish
Résumé
Influenza is a contagious respiratory illness that can cause life-threatening complications among high-risk groups. Estimating the economic burden of influenza is essential to guide policy-making on influenza vaccination programmes, especially in resource-limited settings. This study aimed to estimate the economic burden of influenza on older adults (those aged ≥60 years) in Malaysia from the provider's perspective. The main data source in this study was the MY-DRG Casemix database of a teaching hospital in Malaysia. Cases with principal and secondary diagnoses coded in the International Classification of Diseases version 10 (ICD-10) as J09, J10.0, J10.1, J10.8, J11.0, J11.1, J11.8, J12.8, and J12.9, which represent influenza and its complications, were included in the study. The direct cost of influenza at all severity levels was calculated from the casemix data and guided by a clinical pathway developed by experts. The effect of the variations in costs and incidence rate of influenza for both the casemix and clinical pathway costing approaches was assessed with sensitivity analysis. A total of 1,599 inpatient and 407 outpatient influenza cases were identified from the MY-DRG Casemix database. Most hospitalised cases were aged <18 years (90.6%), while 77 cases (4.8%) involved older people. Mild, moderate, and severe cases comprised 56.5%, 35.1%, and 8.4% of cases, respectively. The estimated average annual direct costs for managing mild, moderate, and severe influenza were RM2,435 (USD579), RM6,504 (USD1,549), and RM13,282 (USD3,163), respectively. The estimated total annual economic burden of influenza on older adults in Malaysia was RM3.28 billion (USD782 million), which was equivalent to 10.7% of the Ministry of Health Malaysia budget for 2020. The sensitivity analysis indicated that the influenza incidence rate and cost of managing severe influenza were the most important factors influencing the total economic burden. Overall, our results demonstrated that influenza imposes a substantial economic burden on the older Malaysian population. The high cost of influenza suggested that further efforts are required to implement a preventive programme, such as immunisation for older people, to reduce the disease and economic burdens.
Sections du résumé
BACKGROUND
BACKGROUND
Influenza is a contagious respiratory illness that can cause life-threatening complications among high-risk groups. Estimating the economic burden of influenza is essential to guide policy-making on influenza vaccination programmes, especially in resource-limited settings. This study aimed to estimate the economic burden of influenza on older adults (those aged ≥60 years) in Malaysia from the provider's perspective.
METHODS
METHODS
The main data source in this study was the MY-DRG Casemix database of a teaching hospital in Malaysia. Cases with principal and secondary diagnoses coded in the International Classification of Diseases version 10 (ICD-10) as J09, J10.0, J10.1, J10.8, J11.0, J11.1, J11.8, J12.8, and J12.9, which represent influenza and its complications, were included in the study. The direct cost of influenza at all severity levels was calculated from the casemix data and guided by a clinical pathway developed by experts. The effect of the variations in costs and incidence rate of influenza for both the casemix and clinical pathway costing approaches was assessed with sensitivity analysis.
RESULTS
RESULTS
A total of 1,599 inpatient and 407 outpatient influenza cases were identified from the MY-DRG Casemix database. Most hospitalised cases were aged <18 years (90.6%), while 77 cases (4.8%) involved older people. Mild, moderate, and severe cases comprised 56.5%, 35.1%, and 8.4% of cases, respectively. The estimated average annual direct costs for managing mild, moderate, and severe influenza were RM2,435 (USD579), RM6,504 (USD1,549), and RM13,282 (USD3,163), respectively. The estimated total annual economic burden of influenza on older adults in Malaysia was RM3.28 billion (USD782 million), which was equivalent to 10.7% of the Ministry of Health Malaysia budget for 2020. The sensitivity analysis indicated that the influenza incidence rate and cost of managing severe influenza were the most important factors influencing the total economic burden.
CONCLUSIONS
CONCLUSIONS
Overall, our results demonstrated that influenza imposes a substantial economic burden on the older Malaysian population. The high cost of influenza suggested that further efforts are required to implement a preventive programme, such as immunisation for older people, to reduce the disease and economic burdens.
Identifiants
pubmed: 37971972
doi: 10.1371/journal.pone.0294260
pii: PONE-D-23-20192
pmc: PMC10653489
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0294260Informations de copyright
Copyright: © 2023 Mad Tahir et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Vaccine. 2007 Jun 28;25(27):5086-96
pubmed: 17544181
Vaccine. 2018 Jun 22;36(27):3960-3966
pubmed: 29801998
Inquiry. 2020 Jan-Dec;57:46958020982925
pubmed: 33355022
Influenza Other Respir Viruses. 2022 May;16(3):376-385
pubmed: 35122389
Pak J Med Sci. 2014 Sep;30(5):1068-71
pubmed: 25225528
Med J Malaysia. 2015 Jun;70(3):127-30
pubmed: 26248773
Influenza Other Respir Viruses. 2018 Jan;12(1):113-121
pubmed: 29243369
BMC Med. 2020 Apr 14;18(1):90
pubmed: 32284056
J Infect. 2014 Apr;68(4):363-71
pubmed: 24291062
N Engl J Med. 2015 Jul 30;373(5):415-27
pubmed: 26172429
Health Econ Rev. 2016 Dec;6(1):53
pubmed: 27896782
BMC Infect Dis. 2021 Jul 5;21(1):644
pubmed: 34225647
Influenza Other Respir Viruses. 2020 May;14(3):286-293
pubmed: 32022411
Adv Ther. 2023 Apr;40(4):1601-1627
pubmed: 36790682
PLoS One. 2017 Sep 5;12(9):e0184410
pubmed: 28873473
BMC Infect Dis. 2022 Dec 15;22(1):943
pubmed: 36522615
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
BMC Health Serv Res. 2018 Jan 25;18(1):38
pubmed: 29370785
PLoS One. 2017 Jan 3;12(1):e0169344
pubmed: 28046080
PLoS One. 2018 Sep 7;13(9):e0202787
pubmed: 30192781
Influenza Other Respir Viruses. 2008 May;2(3):81-92
pubmed: 19453467
J Med Virol. 2023 Jan;95(1):e28153
pubmed: 36110064
Lancet Respir Med. 2019 Jan;7(1):69-89
pubmed: 30553848